13 news items
German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount
BMY
EVO
LLY
20 Jun 24
. (NYSE:LLY), focusing on developing treatments for chronic kidney disease, neuroscience, and metabolic disorders.
Most
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial
BMY
4 Jun 24
include hyperacute graft-versus-host-disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity
Bristol Myers Squibb's Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting
BMY
3 Jun 24
at least one prior line of therapy, and for the treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after two
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
BMY
3 Jun 24
complications include hyperacute graft-versus-host-disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity
FDA Expands Approval For Bristol Myers Squibb's Breyanzi, Making CAR T Cell Therapy Available For Broadest Range Of B-Cell Malignancies
BMY
31 May 24
for Breyanzi for relapsed or refractory chronic lymphocytic leukemia
92gg84d5oiwmdhf56my
BMY
30 May 24
, and has received accelerated approval for the treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after
1fqpvlys0aejnauim8viw18tnxr99di
BMY
23 May 24
(lisocabtagene maraleucel), demonstrating consistent clinical outcomes in relapsed/refractory chronic lymphocytic
61cars6nzo aehoze7f4e1uqwb2vnm9i6bvb0
BMY
16 May 24
that provides sustained relief from this chronic disease, allowing patients to prioritize other aspects of their daily lives. These findings further reinforce
gtsnaz
BMY
15 May 24
lymphoma (LBCL) after at least one prior line of therapy and received accelerated approval for the treatment of relapsed or refractory chronic lymphocytic
ogzqbnksp967c xnck
BMY
10 May 24
hyperacute graft-versus-host-disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning
gdulzjuh1vnqp0cx9al1lirfczvpobdovv89 ch77ap2b5h7xqm7o6hun1ew
BMY
26 Apr 24
(GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning, and steroid-requiring febrile syndrome
zv0r4tig
BMY
25 Apr 24
of Abecma in Earlier-Line Multiple Myeloma and Breyanzi in Chronic
snzkfbajwwa1oponjmmhalc1yter60ngu84pph5fe1r6
BMY
25 Mar 24
agents, fibrinolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. APPRAISE-2, a placebo-controlled clinical trial
- Prev
- 1
- Next